{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:31:29Z","timestamp":1786444289088,"version":"build-2736575974"},"reference-count":164,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15767","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:04:02Z","timestamp":1784117042000},"page":"1-17","source":"Crossref","is-referenced-by-count":0,"title":["Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"Lijuan","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongsheng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ramos\u2011Molina","sequence":"additional","affiliation":[{"name":"Obesity, Diabetes and Metabolism Laboratory, Biomedical Research Institute of Murcia, Murcia 30120, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanchun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"key20260811124540_b1-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"189620","DOI":"10.1016\/j.bbcan.2026.189620","article-title":"Furin-like enzyme dependency in KRAS-mutant colorectal cancer as a target for personalized treatment strategies","volume":"1881","author":"Siegfried","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20260811124540_b2-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41388-021-02175-9","article-title":"The proprotein convertase furin in cancer: More than an oncogene","volume":"41","author":"He","year":"2022","journal-title":"Oncogene"},{"key":"key20260811124540_b3-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"key20260811124540_b4-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MOL.0000000000000601","article-title":"Proprotein convertase subtilisin\/kexin type 9 and lipid metabolism","volume":"30","author":"Spolitu","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"key20260811124540_b5-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"key20260811124540_b6-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-022-02477-0","article-title":"PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260811124540_b7-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"764038","DOI":"10.3389\/fcvm.2021.764038","article-title":"Regulation of PCSK9 expression and function: Mechanisms and therapeutic implications","volume":"8","author":"Xia","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"key20260811124540_b8-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"key20260811124540_b9-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"158660","DOI":"10.1016\/j.bbalip.2020.158660","article-title":"The role of the C-terminal domain of PCSK9 and SEC24 isoforms in PCSK9 secretion","volume":"1865","author":"Deng","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"key20260811124540_b10-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"101662","DOI":"10.1016\/j.molmet.2022.101662","article-title":"Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels","volume":"67","author":"Fruchart Gaillard","year":"2023","journal-title":"Mol Metab"},{"key":"key20260811124540_b11-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2019.08.020","article-title":"The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9","volume":"289","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2019","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b12-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"key":"key20260811124540_b13-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"eaax9198","DOI":"10.1126\/science.aax9198","article-title":"A genome-wide transcriptomic analysis of protein-coding genes in human blood cells","volume":"366","author":"Uhlen","year":"2019","journal-title":"Science"},{"key":"key20260811124540_b14-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: A review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key20260811124540_b15-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2008.10.007","article-title":"Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage","volume":"203","author":"Cameron","year":"2009","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b16-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3389\/fgene.2020.01020","article-title":"PCSK9 variants in familial hypercholesterolemia: A comprehensive synopsis","volume":"11","author":"Guo","year":"2020","journal-title":"Front Genet"},{"key":"key20260811124540_b17-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1194\/jlr.M010009","article-title":"Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population","volume":"51","author":"Guella","year":"2010","journal-title":"J Lipid Res"},{"key":"key20260811124540_b18-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1161\/ATVBAHA.111.240549","article-title":"Common and low-frequency genetic variants in the pcsk9 locus influence circulating PCSK9 levels","volume":"32","author":"Chernogubova","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20260811124540_b19-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/ATVBAHA.114.304406","article-title":"PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: A cross-sectional cohort study","volume":"34","author":"Saavedra","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20260811124540_b20-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key20260811124540_b21-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jacl.2018.04.004","article-title":"R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction","volume":"12","author":"Mostaza","year":"2018","journal-title":"J Clin Lipidol"},{"key":"key20260811124540_b22-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key20260811124540_b23-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","article-title":"PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction","volume":"42","author":"Da Dalt","year":"2021","journal-title":"Eur Heart J"},{"key":"key20260811124540_b24-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.numecd.2024.04.007","article-title":"Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis","volume":"34","author":"Liu","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"key20260811124540_b25-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1399-0004.2007.00807.x","article-title":"Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia","volume":"71","author":"Taylor","year":"2007","journal-title":"Clin Genet"},{"key":"key20260811124540_b26-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: Relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J Med Genet"},{"key":"key20260811124540_b27-ol-32-3-15767","first-page":"266","article-title":"PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia","volume":"18","author":"Kaya","year":"2017","journal-title":"Anatol J Cardiol"},{"key":"key20260811124540_b28-ol-32-3-15767","first-page":"334","article-title":"Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia","volume":"19","author":"Ero\u011flu","year":"2018","journal-title":"Anatol J Cardiol"},{"key":"key20260811124540_b29-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1373\/clinchem.2009.129759","article-title":"Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9","volume":"55","author":"Humphries","year":"2009","journal-title":"Clin Chem"},{"key":"key20260811124540_b30-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.atherosclerosis.2007.07.019","article-title":"Familial hypercholesterolaemia in Portugal","volume":"196","author":"Bourbon","year":"2008","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b31-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2014.06.005","article-title":"Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutation","volume":"236","author":"Mabuchi","year":"2014","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b32-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jacl.2015.12.024","article-title":"Proprotein convertase subtilisin\/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia","volume":"10","author":"Ohta","year":"2016","journal-title":"J Clin Lipidol"},{"key":"key20260811124540_b33-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2009.11.018","article-title":"The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation","volume":"210","author":"Noguchi","year":"2010","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b34-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"156077","DOI":"10.1016\/j.cyto.2022.156077","article-title":"The impact of the PCSK-9\/VLDL-receptor axis on inflammatory cell polarization","volume":"161","author":"Barcena","year":"2023","journal-title":"Cytokine"},{"key":"key20260811124540_b35-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"key":"key20260811124540_b36-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase Subtilisin\/Kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One"},{"key":"key20260811124540_b37-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/cvr\/cvaa254","article-title":"PCSK9 and LRP5 in macrophage lipid internalization and inflammation","volume":"117","author":"Badimon","year":"2021","journal-title":"Cardiovasc Res"},{"key":"key20260811124540_b38-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects Long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20260811124540_b39-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression","volume":"50","author":"Labont\u0301e","year":"2009","journal-title":"Hepatology"},{"key":"key20260811124540_b40-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"23385","DOI":"10.1074\/jbc.M115.642991","article-title":"Plasma membrane tetraspanin CD81 complexes with proprotein convertase subtilisin\/kexin type 9 (PCSK9) and low density lipoprotein receptor (LDLR), and Its levels are reduced by PCSK9","volume":"290","author":"Le","year":"2015","journal-title":"J Biol Chem"},{"key":"key20260811124540_b41-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/v15020360","article-title":"SKI-1\/S1P Facilitates SARS-CoV-2 spike induced Cell-to-Cell fusion via activation of SREBP-2 and Metalloproteases, Whereas PCSK9 enhances the degradation of ACE2","volume":"15","author":"Essalmani","year":"2023","journal-title":"Viruses"},{"key":"key20260811124540_b42-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"111194","DOI":"10.1016\/j.celrep.2022.111194","article-title":"S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K\/AKT pathway","volume":"40","author":"Sun","year":"2022","journal-title":"Cell Rep"},{"key":"key20260811124540_b43-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/embor.2008.132","article-title":"PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1","volume":"9","author":"Jonas","year":"2008","journal-title":"EMBO Rep"},{"key":"key20260811124540_b44-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"key20260811124540_b45-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12885-024-12148-2","article-title":"Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"key20260811124540_b46-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00404-021-06215-3","article-title":"Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer","volume":"305","author":"Lin","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"key20260811124540_b47-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13402-022-00694-5","article-title":"Cholesterol homeostasis and cancer: A new perspective on the low-density lipoprotein receptor","volume":"45","author":"Gu","year":"2022","journal-title":"Cell Oncol"},{"key":"key20260811124540_b48-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s11883-022-01057-z","article-title":"Expanding biology of PCSK9: Roles in atherosclerosis and beyond","volume":"24","author":"Seidah","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"key20260811124540_b49-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"key20260811124540_b50-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1038\/s41388-023-02836-x","article-title":"Dysregulation of cholesterol metabolism in cancer progression","volume":"42","author":"Liu","year":"2023","journal-title":"Oncogene"},{"key":"key20260811124540_b51-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2407-12-25","article-title":"Cholesterol and the risk of grade-specific prostate cancer incidence: Evidence from two large prospective cohort studies with up to 37 years' follow up","volume":"12","author":"Shafique","year":"2012","journal-title":"BMC Cancer"},{"key":"key20260811124540_b52-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11894-025-01008-z","article-title":"The impact of cholecystectomy on colorectal cancer risk: A comprehensive review on risk factors and the association","volume":"27","author":"Lorestani","year":"2025","journal-title":"Curr Gastroenterol Rep"},{"key":"key20260811124540_b53-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/CEJ.0000000000000597","article-title":"Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: A systematic review and meta-analysis of observational epidemiologic studies","volume":"30","author":"Zhang","year":"2021","journal-title":"Eur J Cancer Prev"},{"key":"key20260811124540_b54-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"114654","DOI":"10.1016\/j.bcp.2021.114654","article-title":"Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs","volume":"196","author":"Patel","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"key20260811124540_b55-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/hsz-2014-0194","article-title":"Cholesterol lowering: Role in cancer prevention and treatment","volume":"396","author":"Murai","year":"2015","journal-title":"Biol Chem"},{"key":"key20260811124540_b56-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/cam4.1987","article-title":"Correlation between immune signature and high-density lipoprotein cholesterol level in stage II\/III colorectal cancer","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"key":"key20260811124540_b57-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1476-511X-13-16","article-title":"LDL-cholesterol signaling induces breast cancer proliferation and invasion","volume":"13","author":"Rodrigues Dos Santos","year":"2014","journal-title":"Lipids Health Dis"},{"key":"key20260811124540_b58-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.3390\/ijms22084114","article-title":"Pcsk9 induces rat smooth muscle cell proliferation and counteracts the pleiotropic effects of simvastatin","volume":"22","author":"Lupo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20260811124540_b59-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"151081","DOI":"10.1016\/j.bbrc.2024.151081","article-title":"PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagy","volume":"742","author":"Zhang","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"key20260811124540_b60-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/cbin.12018","article-title":"PCSK9 inhibitor attenuates atherosclerosis by regulating SNHG16\/EZH2\/TRAF5-mediated VSMC proliferation, migration, and foam cell formation","volume":"47","author":"Liu","year":"2023","journal-title":"Cell Biol Int"},{"key":"key20260811124540_b61-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1016\/j.stemcr.2021.10.004","article-title":"PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs","volume":"16","author":"Roudaut","year":"2021","journal-title":"Stem Cell Reports"},{"key":"key20260811124540_b62-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement","volume":"253","author":"Ferri","year":"2016","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b63-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"key20260811124540_b64-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"},{"key":"key20260811124540_b65-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3892\/ol.2023.14086","article-title":"PCSK9 promotes tumor cell proliferation and migration by facilitating CCL25 secretion in esophageal squamous cell carcinoma","volume":"26","author":"Wang","year":"2023","journal-title":"Oncol Lett"},{"key":"key20260811124540_b66-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3892\/etm.2017.4218","article-title":"PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways","volume":"13","author":"Xu","year":"2017","journal-title":"Exp Ther Med"},{"key":"key20260811124540_b67-ol-32-3-15767","first-page":"2787","article-title":"PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways","volume":"8","author":"Piao","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20260811124540_b68-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"6929","DOI":"10.18632\/oncotarget.14322","article-title":"A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"key20260811124540_b69-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-021-00218-1","article-title":"PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"key20260811124540_b70-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"609663","DOI":"10.3389\/fonc.2020.609663","article-title":"Proprotein convertase subtilisin\/kexin type 9 promotes gastric cancer metastasis and suppresses apoptosis by facilitating MAPK signaling pathway through HSP70 Up-regulation","volume":"10","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"key20260811124540_b71-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5114\/aoms.2020.91291","article-title":"Effects of immunisation against PCSK9 in mice bearing melanoma","volume":"16","author":"Momtazi-Borojeni","year":"2020","journal-title":"Arch Med Sci"},{"key":"key20260811124540_b72-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"570","DOI":"10.5114\/aoms.2019.84734","article-title":"Effects of immunization against PCSK9 in an experimental model of breast cancer","volume":"15","author":"Momtazi-Borojeni","year":"2019","journal-title":"Arch Med Sci"},{"key":"key20260811124540_b73-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5114\/aoms.2019.84732","article-title":"Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer","volume":"15","author":"Momtazi-Borojeni","year":"2019","journal-title":"Arch Med Sci"},{"key":"key20260811124540_b74-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.2020.0150","article-title":"Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian cancer","volume":"323","author":"Yarmolinsky","year":"2020","journal-title":"JAMA"},{"key":"key20260811124540_b75-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","article-title":"Invasion and metastasis in cancer: Molecular insights and therapeutic targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"key20260811124540_b76-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1023\/A:1026448026716","article-title":"Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma","volume":"17","author":"Matar","year":"1999","journal-title":"Clin Exp Metastasis"},{"key":"key20260811124540_b77-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/gast.2002.31093","article-title":"3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis","volume":"122","author":"Kusama","year":"2002","journal-title":"Gastroenterology"},{"key":"key20260811124540_b78-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2407-14-132","article-title":"Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression","volume":"14","author":"Rodrigues dos Santos","year":"2014","journal-title":"BMC Cancer"},{"key":"key20260811124540_b79-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/nu17091445","article-title":"(\u2212)-Oleuropein as a novel metastatic Castration-resistant prostate cancer progression and recurrence suppressor via targeting PCSK9-LDLR axis","volume":"17","author":"Ahmed","year":"2025","journal-title":"Nutrients"},{"key":"key20260811124540_b80-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2101470","DOI":"10.1183\/13993003.01470-2021","article-title":"Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content","volume":"60","author":"L\u00f3pez-Alonso","year":"2022","journal-title":"Eur Respir J"},{"key":"key20260811124540_b81-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.neo.2021.07.007","article-title":"Proprotein convertase subtilisin\/kexin Type 9 is required for Ahnak-mediated metastasis of melanoma into lung epithelial cells","volume":"23","author":"Suh","year":"2021","journal-title":"Neoplasia"},{"key":"key20260811124540_b82-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41586-025-09017-8","article-title":"PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer","volume":"643","author":"Rademaker","year":"2025","journal-title":"Nature"},{"key":"key20260811124540_b83-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41586-023-06878-9","article-title":"7-Dehydrocholesterol is an endogenous suppressor of ferroptosis","volume":"626","author":"Freitas","year":"2024","journal-title":"Nature"},{"key":"key20260811124540_b84-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e18018","DOI":"10.7717\/peerj.18018","article-title":"Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer","volume":"12","author":"Xu","year":"2024","journal-title":"PeerJ"},{"key":"key20260811124540_b85-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2024.11.009","article-title":"A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor","volume":"188","author":"Mei","year":"2025","journal-title":"Cell"},{"key":"key20260811124540_b86-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: From mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"key20260811124540_b87-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.7150\/ijbs.92274","article-title":"Cholesterol metabolism in tumor microenvironment: Cancer hallmarks and therapeutic opportunities","volume":"20","author":"Jiang","year":"2024","journal-title":"Int J Biol Sci"},{"key":"key20260811124540_b88-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41467-022-31663-z","article-title":"The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"key20260811124540_b89-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2147\/OTT.S129413","article-title":"Inhibition of PCSK9 protects against radiationinduced damage of prostate cancer cells","volume":"10","author":"Gan","year":"2017","journal-title":"Onco Targets Ther"},{"key":"key20260811124540_b90-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/JN9.0000000000000019","article-title":"Cholesterol metabolism and tumor radiotherapy","volume":"8","author":"Kuang","year":"2023","journal-title":"J Nutr Oncol"},{"key":"key20260811124540_b91-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.7150\/jca.38598","article-title":"Role of de novo cholesterol synthesis enzymes in cancer","volume":"11","author":"Yang","year":"2020","journal-title":"J Cancer"},{"key":"key20260811124540_b92-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/cancers15010003","article-title":"Rewiring lipid metabolism by targeting PCSK9 and HMGCR to treat liver cancer","volume":"15","author":"Alannan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260811124540_b93-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cmet.2019.02.011","article-title":"Mitochondria bound to lipid droplets: Where mitochondrial dynamics regulate lipid storage and utilization","volume":"29","author":"Benador","year":"2019","journal-title":"Cell Metab"},{"key":"key20260811124540_b94-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/cells12010062","article-title":"Targeting PCSK9 in liver cancer cells triggers metabolic exhaustion and cell death by ferroptosis","volume":"12","author":"Alannan","year":"2022","journal-title":"Cells"},{"key":"key20260811124540_b95-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20260811124540_b96-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"155291","DOI":"10.1016\/j.metabol.2022.155291","article-title":"Pancreatic PCSK9 controls the organization of the \u03b2-cell secretory pathway via LDLR-cholesterol axis","volume":"136","author":"Marku","year":"2022","journal-title":"Metabolism"},{"key":"key20260811124540_b97-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20260811124540_b98-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<560::AID-IJC10>3.0.CO;2-7","article-title":"Lovastatin and tumor necrosis factor-\u03b1 exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor Via inhibition of tumor-induced angiogenesis","volume":"81","author":"Feleszko","year":"1999","journal-title":"Int J Cancer"},{"key":"key20260811124540_b99-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"147051","DOI":"10.1016\/j.gene.2022.147051","article-title":"A novel angiogenic effect of PCSK9-regulated genes","volume":"852","author":"Zhan","year":"2023","journal-title":"Gene"},{"key":"key20260811124540_b100-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1139\/cjpp-2018-0542","article-title":"Evolocumab, a proprotein convertase subtilisin\/kexin type 9 inhibitor, promotes angiogenesis in vitro","volume":"97","author":"Safaeian","year":"2019","journal-title":"Can J Physiol Pharmacol"},{"key":"key20260811124540_b101-ol-32-3-15767","article-title":"Inhibition of proprotein convertase subtilisin-like kexin type 9 (PCSK9) potentiates anti-angiogenic therapy in colorectal cancer liver metastases","author":"Rada","year":"2023","journal-title":"bioRxiv"},{"key":"key20260811124540_b102-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"key20260811124540_b103-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1579054","DOI":"10.3389\/fonc.2025.1579054","article-title":"Cholesterol effects on the tumor immune microenvironment: From fundamental concepts to mechanisms and implications","volume":"15","author":"Lagunas-Rangel","year":"2025","journal-title":"Front Oncol"},{"key":"key20260811124540_b104-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e22885","DOI":"10.1016\/j.heliyon.2023.e22885","article-title":"The combined characteristics of cholesterol metabolism and the immune microenvironment may serve as valuable biomarkers for both the prognosis and treatment of hepatocellular carcinoma","volume":"9","author":"Bai","year":"2023","journal-title":"Heliyon"},{"key":"key20260811124540_b105-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"216208","DOI":"10.1016\/j.canlet.2023.216208","article-title":"Myeloid-derived suppressor cells deficient in cholesterol biosynthesis promote tumor immune evasion","volume":"564","author":"Chen","year":"2023","journal-title":"Cancer Lett"},{"key":"key20260811124540_b106-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein Cell"},{"key":"key20260811124540_b107-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/ATVBAHA.123.320391","article-title":"Disruption of PCSK9 suppresses inflammation and attenuates abdominal aortic aneurysm formation","volume":"45","author":"Peng","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20260811124540_b108-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.ajpath.2020.07.016","article-title":"Leptin, resistin, and proprotein convertase Subtilisin\/Kexin Type 9: The role of STAT3","volume":"190","author":"Macchi","year":"2020","journal-title":"Am J Pathol"},{"key":"key20260811124540_b109-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40364-024-00712-8","article-title":"PCSK9 in T-cell function and the immune response","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark Res"},{"key":"key20260811124540_b110-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-\u03baB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int J Mol Med"},{"key":"key20260811124540_b111-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci Rep"},{"key":"key20260811124540_b112-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"7685796","DOI":"10.1155\/2022\/7685796","article-title":"PCSK9 modulates macrophage polarization-mediated ventricular remodeling after myocardial infarction","volume":"2022","author":"Wang","year":"2022","journal-title":"J Immunol Res"},{"key":"key20260811124540_b113-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.3390\/ijms23169114","article-title":"Functional crosstalk between PCSK9 internalization and Pro-inflammatory activation in human macrophages: Role of reactive oxygen species release","volume":"23","author":"Ja\u00e9n","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20260811124540_b114-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCRESAHA.121.320056","article-title":"Proprotein convertase Subtilisin\/Kexin 9 (PCSK9) promotes macrophage activation via LDL Receptor-independent mechanisms","volume":"131","author":"Katsuki","year":"2022","journal-title":"Circ Res"},{"key":"key20260811124540_b115-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/joim.12758","article-title":"PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque","volume":"284","author":"Liu","year":"2018","journal-title":"J Intern Med"},{"key":"key20260811124540_b116-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1007\/s11845-023-03323-8","article-title":"Circulating PCSK9 relates to aggravated disease activity, Th17\/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients","volume":"192","author":"Meng","year":"2023","journal-title":"Ir J Med Sci"},{"key":"key20260811124540_b117-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/cac2.70038","article-title":"Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy","volume":"45","author":"Lao","year":"2025","journal-title":"Cancer Commun"},{"key":"key20260811124540_b118-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1142428","DOI":"10.3389\/fimmu.2023.1142428","article-title":"PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer","volume":"14","author":"Gao","year":"2023","journal-title":"Front Immunol"},{"key":"key20260811124540_b119-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"947756","DOI":"10.3389\/fimmu.2022.947756","article-title":"Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"key20260811124540_b120-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-022-02584-y","article-title":"PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity","volume":"42","author":"Gu","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260811124540_b121-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"106916","DOI":"10.1016\/j.isci.2023.106916","article-title":"Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer","volume":"26","author":"Yang","year":"2023","journal-title":"iScience"},{"key":"key20260811124540_b122-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/hep4.1858","article-title":"Pcsk9 deletion promotes murine nonalcoholic steatohepatitis and hepatic carcinogenesis: Role of cholesterol","volume":"6","author":"Ioannou","year":"2022","journal-title":"Hepatol Commun"},{"key":"key20260811124540_b123-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1080\/08820139.2022.2027439","article-title":"PCSK9 suppresses M2-Like Tumor-associated macrophage polarization by regulating the secretion of OX40L from Hepatocellular carcinoma cells","volume":"51","author":"Hu","year":"2022","journal-title":"Immunol Invest"},{"key":"key20260811124540_b124-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jacl.2021.09.007","article-title":"Circulating Levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers","volume":"16","author":"Chong","year":"2022","journal-title":"J Clin Lipidol"},{"key":"key20260811124540_b125-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00262-019-02367-z","article-title":"Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: A pilot study","volume":"68","author":"Bonaventura","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"key20260811124540_b126-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1759-7714.14259","article-title":"Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"13","author":"Xie","year":"2022","journal-title":"Thorac Cancer"},{"key":"key20260811124540_b127-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin Chem"},{"key":"key20260811124540_b128-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/eurjpc\/zwae368","article-title":"PCSK9 inhibitor with cause-specific mortality amongst cancer survivors : A chance to kill two birds with one stone","volume":"33","author":"Zhang","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"key20260811124540_b129-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/genes15010132","article-title":"The causal relationship between PCSK9 inhibitors and malignant tumors: A mendelian randomization study based on drug targeting","volume":"15","author":"Wang","year":"2024","journal-title":"Genes (Basel)"},{"key":"key20260811124540_b130-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1186\/s12885-022-10120-6","article-title":"Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers","volume":"22","author":"Wong Chong","year":"2022","journal-title":"BMC Cancer"},{"key":"key20260811124540_b131-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1515\/oncologie-2024-0542","article-title":"Prognostic implications of PCSK9 expression in HER2-positive breast cancer","volume":"27","author":"Wu","year":"2025","journal-title":"Oncologie"},{"key":"key20260811124540_b132-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1134063","DOI":"10.3389\/fonc.2023.1134063","article-title":"Identification and validation of PCSK9 as a prognostic and immune-related influencing factor in tumorigenesis: A pan-cancer analysis","volume":"13","author":"Sun","year":"2023","journal-title":"Front Oncol"},{"key":"key20260811124540_b133-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"708039","DOI":"10.3389\/fonc.2021.708039","article-title":"Association of serum Anti-PCSK9 antibody levels with favorable postoperative prognosis in esophageal cancer","volume":"11","author":"Ito","year":"2021","journal-title":"Front Oncol"},{"key":"key20260811124540_b134-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e010395","DOI":"10.1136\/jitc-2024-010395","article-title":"Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): Safety, efficacy, and exploratory biomarker analysis","volume":"13","author":"Wood","year":"2025","journal-title":"J Immunother Cancer"},{"key":"key20260811124540_b135-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med"},{"key":"key20260811124540_b136-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e0220254","DOI":"10.1371\/journal.pone.0220254","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study","volume":"14","author":"Picard","year":"2019","journal-title":"PLoS One"},{"key":"key20260811124540_b137-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"key20260811124540_b138-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e22626","DOI":"10.1096\/fj.202201195R","article-title":"PTEN-knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid","volume":"36","author":"Wang","year":"2022","journal-title":"FASEB J"},{"key":"key20260811124540_b139-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s12275-019-9320-3","article-title":"Pten gene deletion in intestinal epithelial cells enhances susceptibility to Salmonella Typhimurium infection in mice","volume":"57","author":"Howe","year":"2019","journal-title":"J Microbiol"},{"key":"key20260811124540_b140-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s12276-023-01079-w","article-title":"Functional significance of cholesterol metabolism in cancer: From threat to treatment","volume":"55","author":"Xiao","year":"2023","journal-title":"Exp Mol Med"},{"key":"key20260811124540_b141-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17425255.2020.1828343","article-title":"An update on PCSK9 inhibitors-pharmacokinetics, drug interactions, and toxicity","volume":"16","author":"Mo\u015fteoru","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20260811124540_b142-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","article-title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program","volume":"278","author":"Farnier","year":"2018","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b143-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2019.08.004","article-title":"Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients","volume":"289","author":"Hori","year":"2019","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b144-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b145-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/ATVBAHA.120.315040","article-title":"Cascade screening for familial hypercholesterolemia in south africa: The Wits FIND-FH program","volume":"40","author":"Raal","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20260811124540_b146-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pharmtox-010716-104944","article-title":"PCSK9: Regulation and target for drug development for dyslipidemia","volume":"57","author":"Burke","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key20260811124540_b147-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/gim.2015.71","article-title":"Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: Considerations for genetic diagnosis improvement","volume":"18","author":"Medeiros","year":"2016","journal-title":"Genet Med"},{"key":"key20260811124540_b148-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2017.02.007","article-title":"The genetic spectrum of familial hypercholesterolemia in the central south region of China","volume":"258","author":"Xiang","year":"2017","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b149-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s10557-024-07599-5","article-title":"PCSK9 and lipid metabolism: Genetic variants, current therapies, and cardiovascular outcomes","volume":"39","author":"Grejtakova","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"key20260811124540_b150-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/metabo12030256","article-title":"Insight into the Evolving role of PCSK9","volume":"12","author":"Malig\u0142\u00f3wka","year":"2022","journal-title":"Metabolites"},{"key":"key20260811124540_b151-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/pro.3019","article-title":"Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor","volume":"25","author":"Garvie","year":"2016","journal-title":"Protein Sci"},{"key":"key20260811124540_b152-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cca.2013.03.017","article-title":"The genetic spectrum of familial hypercholesterolemia in Pakistan","volume":"421","author":"Ahmed","year":"2013","journal-title":"Clin Chim Acta"},{"key":"key20260811124540_b153-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.3390\/ijms24043330","article-title":"Functional characterization of p.(Arg160Gln) PCSK9 variant accidentally found in a hypercholesterolemic subject","volume":"24","author":"Larrea-Sebal","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260811124540_b154-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.atherosclerosis.2007.07.022","article-title":"Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa","volume":"196","author":"Homer","year":"2008","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b155-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"13602","DOI":"10.3390\/ijms222413602","article-title":"A systematic approach to assess the activity and classification of pcsk9 variants","volume":"22","author":"Uribe","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20260811124540_b156-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12967-018-1737-7","article-title":"Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease","volume":"16","author":"Cao","year":"2018","journal-title":"J Transl Med"},{"key":"key20260811124540_b157-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"aaf7000","DOI":"10.1126\/science.aaf7000","article-title":"Genetic identification of familial hypercholesterolemia within a single U.S. Health care system","volume":"354","author":"Abul-Husn","year":"2016","journal-title":"Science"},{"key":"key20260811124540_b158-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Hyock","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20260811124540_b159-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2006.10.003","article-title":"Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic","volume":"194","author":"Tosi","year":"2007","journal-title":"Atherosclerosis"},{"key":"key20260811124540_b160-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4068\/cmj.2018.54.1.31","article-title":"Detection of familial hypercholesterolemia using next generation sequencing in two Population-based cohorts","volume":"54","author":"Kim","year":"2018","journal-title":"Chonnam Med J"},{"key":"key20260811124540_b161-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jacl.2019.04.099","article-title":"The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia","volume":"13","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2019","journal-title":"J Clin Lipidol"},{"key":"key20260811124540_b162-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20260811124540_b163-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12944-019-1042-3","article-title":"Effects of familial hypercholesterolemia-associated genes on the phenotype of premature myocardial infarction","volume":"18","author":"Lee","year":"2019","journal-title":"Lipids Health Dis"},{"key":"key20260811124540_b164-ol-32-3-15767","doi-asserted-by":"publisher","first-page":"e0186446","DOI":"10.1371\/journal.pone.0186446","article-title":"Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:45:49Z","timestamp":1786441549000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":164,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15767","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}